Overview

Preoperative Octreotide Treatment of Acromegaly

Status:
Completed
Trial end date:
2010-05-01
Target enrollment:
0
Participant gender:
All
Summary
The purpose of this study is to investigate whether 6 months preoperative treatment with the somatostatin analogue octreotide improves the surgical outcome in patients with acromegaly.
Phase:
Phase 4
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
St. Olavs Hospital
Collaborator:
Novartis
Treatments:
Octreotide
Criteria
Inclusion Criteria:

- GH nadir during a standard 75 g OGTT >= 5.0 mmol/L.

- Pituitary tumor by MRI-scan.

Exclusion Criteria:

- Immediate surgery indicated by usual clinical criteria.

- Pregnant.

- Known adverse effects of octreotide.

- Unfit for participation by any other reason.